Medifast (NYSE:MED) Issues Q2 Earnings Guidance

Medifast (NYSE:MED) issued an update on its second quarter earnings guidance on Monday morning. The company provided EPS guidance of $0.05-0.40 for the period, compared to the consensus EPS estimate of $0.68. The company issued revenue guidance of $150-170 million, compared to the consensus revenue estimate of $178.50 million.

Medifast Stock Up 5.3 %

Shares of Medifast stock traded up $1.80 during trading on Monday, reaching $35.51. The company’s stock had a trading volume of 635,994 shares, compared to its average volume of 379,524. The company has a market cap of $387.06 million, a price-to-earnings ratio of 3.86 and a beta of 1.14. Medifast has a 1-year low of $30.95 and a 1-year high of $109.52. The company has a 50-day simple moving average of $36.52 and a two-hundred day simple moving average of $54.69.

Medifast (NYSE:MED) last announced its quarterly earnings data on Tuesday, February 20th. The specialty retailer reported $1.09 EPS for the quarter, beating the consensus estimate of $0.99 by $0.10. Medifast had a net margin of 9.27% and a return on equity of 56.06%. The business had revenue of $191.02 million during the quarter, compared to analysts’ expectations of $184.17 million. During the same period in the previous year, the business posted $3.70 EPS. The business’s quarterly revenue was down 43.4% compared to the same quarter last year. As a group, analysts anticipate that Medifast will post 1.91 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on MED shares. TheStreet lowered shares of Medifast from a c rating to a d+ rating in a research note on Wednesday, February 21st. DA Davidson decreased their target price on Medifast from $67.00 to $40.00 and set a neutral rating on the stock in a research report on Wednesday, February 21st.

Insider Buying and Selling

In related news, Director Scott Schlackman sold 4,053 shares of Medifast stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $39.44, for a total transaction of $159,850.32. Following the transaction, the director now owns 7,785 shares in the company, valued at $307,040.40. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 2.06% of the stock is currently owned by company insiders.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.